Published in Semin Cancer Biol on October 05, 2011
The structural basis for cancer treatment decisions. Oncotarget (2014) 1.05
Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. Breast Cancer Res (2013) 0.96
High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium. Breast Cancer Res (2015) 0.93
Oncogenic HRAS Activates Epithelial-to-Mesenchymal Transition and Confers Stemness to p53-Deficient Urothelial Cells to Drive Muscle Invasion of Basal Subtype Carcinomas. Cancer Res (2015) 0.92
PTTG2 silencing results in induction of epithelial-to-mesenchymal transition and apoptosis. Cell Death Dis (2013) 0.83
Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor. Cancer Med (2013) 0.82
Soiling the seed: microenvironment and epithelial mesenchymal plasticity. Cancer Microenviron (2012) 0.78
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Retracted Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol (2009) 3.84
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell (2013) 2.46
Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol (2003) 2.05
Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. EMBO Rep (2002) 1.79
Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell (2004) 1.71
Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet (2009) 1.55
Influence of neuroblastoma stage on serum-based detection of MYCN amplification. Pediatr Blood Cancer (2009) 1.49
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet (2012) 1.47
Gadd45a activation protects melanoma cells from ultraviolet B-induced apoptosis. J Invest Dermatol (2007) 1.47
A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer (2006) 1.44
MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res (2002) 1.41
Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med (2009) 1.36
p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell (2013) 1.35
The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells (2010) 1.34
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26
Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene (2003) 1.25
Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat (2006) 1.25
Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem (2009) 1.17
p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol (2006) 1.14
CCR4-associated factor CAF1 is an essential factor for spermatogenesis. Mol Cell Biol (2004) 1.13
BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood (2008) 1.10
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat (2011) 1.04
Neurofibromatosis type 1 gene as a mutational target in a mismatch repair-deficient cell type. Hum Genet (2002) 1.03
Antagonistic regulation of EMT by TIF1γ and Smad4 in mammary epithelial cells. EMBO Rep (2011) 1.02
Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients. Cancer Res (2002) 1.02
PLA2R1 mediates tumor suppression by activating JAK2. Cancer Res (2013) 1.01
The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells. J Cell Sci (2005) 0.99
Novel biallelic mutations in MSH6 and PMS2 genes: gene conversion as a likely cause of PMS2 gene inactivation. Hum Mutat (2007) 0.99
Methylome analysis reveals Jak-STAT pathway deregulation in putative breast cancer stem cells. Epigenetics (2011) 0.97
TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. PLoS One (2012) 0.96
BTG2, its family and its tutor. Bull Cancer (2004) 0.94
Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol (2005) 0.93
The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene (2002) 0.93
Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. Cancer Lett (2004) 0.92
Mutational targets in colorectal cancer cells with microsatellite instability. Fam Cancer (2006) 0.91
BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. Oncogene (2002) 0.91
Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett (2005) 0.90
Chfr inactivation is not associated to chromosomal instability in colon cancers. Oncogene (2003) 0.89
Cancer patients who experienced diagnostic genetic testing for cancer susceptibility: reactions and behavior after the disclosure of a positive test result. Cancer Epidemiol Biomarkers Prev (2002) 0.88
TWIST1 expression in breast cancer cells facilitates bone metastasis formation. J Bone Miner Res (2014) 0.88
Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells. J Immunother (2010) 0.88
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer (2008) 0.87
Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. BMC Cancer (2013) 0.87
PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radic Biol Med (2013) 0.87
Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood (2010) 0.87
CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood (2011) 0.86
Variants in the netrin-1 receptor UNC5C prevent apoptosis and increase risk of familial colorectal cancer. Gastroenterology (2011) 0.86
Copper isotope effect in serum of cancer patients. A pilot study. Metallomics (2015) 0.84
Intensity-dependent constitutional MLH1 promoter methylation leads to early onset of colorectal cancer by affecting both alleles. Genes Chromosomes Cancer (2010) 0.84
Tif1γ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development (2012) 0.84
Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer (2002) 0.84
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer. BMC Cancer (2006) 0.84
The SNAIL family member SCRATCH1 is not expressed in human tumors. Oncol Rep (2010) 0.83
Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine. Biochem Pharmacol (2003) 0.82
Polymorphisms and HNPCC: PMS2-MLH1 protein interactions diminished by single nucleotide polymorphisms. Hum Mutat (2002) 0.82
UVB-induced G2 arrest of human melanocytes involves Cdc2 sequestration by Gadd45a in nuclear speckles. Cell Cycle (2006) 0.82
Early origin of cancer metastases: dissemination and evolution of premalignant cells. Cell Cycle (2008) 0.82
Interhelical loops within the bHLH domain are determinant in maintaining TWIST1-DNA complexes. J Biomol Struct Dyn (2013) 0.80
ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells. Mol Cancer (2014) 0.80
βIII-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells. Eur J Cell Biol (2011) 0.78
Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer (2011) 0.78
Weekly administration of paclitaxel induces long-term aneugenicity in nude mice. Cancer Biol Ther (2007) 0.78
Modulation of oxidative stress by twist oncoproteins. PLoS One (2013) 0.76
p21(Cip1) regulates cell-substrate adhesion and interphase microtubule dynamics in untransformed human mammary epithelial cells. Eur J Cell Biol (2011) 0.76
Upstream ORF affects MYCN translation depending on exon 1b alternative splicing. BMC Cancer (2009) 0.75
[Tumour genomics: an unstable landscape]. Bull Cancer (2008) 0.75
Should we consider cancers as embryonic diseases or as consequences of stem-cell deregulation? Clin Med Oncol (2008) 0.75
[Genotypic analysis and immunohistochemistry in human cancers: conflicting or complementary information?]. Ann Pathol (2002) 0.75
[The premature senescence: chimera, saving angel or Dr Jekyll and Mr Hyde?]. Med Sci (Paris) (2009) 0.75
[The key implication of early migration of metastatic cells]. Med Sci (Paris) (2009) 0.75
[microRNA in cancer, small but risky]. Med Sci (Paris) (2008) 0.75
[An alternate model of tumoral progression]. Biol Aujourdhui (2011) 0.75
[Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside]. Bull Cancer (2006) 0.75